Romark Laboratories Responds to Recent Cryptosporidiosis (Crypto) Outbreak in Florida

TAMPA, FL--(Marketwired - Sep 25, 2014) - Romark Laboratories, a Tampa-based pharmaceutical company committed to the discovery, development and commercialization of innovative small molecules for treating infectious diseases, today responded to recent outbreaks of a parasitic disease known as cryptosporidiosis (Crypto) in Tampa and Jacksonville, Florida. 

Crypto is one of the most common causes of waterborne illnesses in the United States, with outbreaks peaking in the summer and early fall. Crypto is most commonly spread through the water -- such as swimming pools -- and can cause serious diarrheal illness.

"It is important for Florida residents to know that they can seek treatment and that they do not need to suffer waiting for Crypto to run its course, which can last from a few days to a few weeks," said Jean-François Rossignol, Ph.D., F.R.S.C., M.D., FRCPath, Chief Science Officer at Romark Laboratories. "The outbreaks in Florida remind us that Crypto is not just a third world problem. If you suspect you or your child has Crypto, the most important thing you can do is see your doctor for proper diagnosis and treatment."

For more information visit www.cdc.gov/parasites/crypto/. 

About Alinia^®
Alinia for Oral Suspension (patients 1 year of age and older) and Alinia Tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum. Alinia for Oral Suspension and Alinia Tablets have not been shown to be superior to placebo for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients

IMPORTANT SAFETY INFORMATION

• Do not take Alinia Tablets or Alinia for Oral Suspension if you are allergic to nitazoxanide or any other ingredient in the formulations.
• Please discuss with your doctor if you have hepatic, biliary, or renal disease, and are taking any other medications like warfarin.
• The most common side effects were abdominal pain, diarrhea, headache, nausea and vomiting, which were also reported by patients taking a placebo (sugar pill).

For more information please read the Full Prescribing Information at www.alinia.com.

About Romark Laboratories
Romark Laboratories, L.C. is a vertically integrated biopharmaceutical company committed to the discovery and development of innovative small molecule drugs for treating infectious diseases. The Company markets Alinia® (nitazoxanide) tablets, 500 mg and Alinia (nitazoxanide) for Oral Suspension, 100 mg/ 5 mL in the United States through a specialty sales force focused on gastroenterologists and infectious disease specialists.

Romark is developing a class of small molecule drugs called thiazolides. The Company's product, NT-300 (nitazoxanide), is presently undergoing Phase 3 clinical development on a global basis for treatment of acute uncomplicated influenza. Other new drugs from the Company's platform technology are proposed for treatment of viral diseases and cancers.

Alinia is a trademark of Romark Laboratories, L.C.
Alinia^® for Oral Suspension is distributed by Lupin Pharmaceuticals, Inc. under license from Romark Laboratories, L.C.

RM-AL-027-01V1 R09.14